The Association of Community Cancer Centers has released consensus-based Oncology Financial Advocacy Services Guidelines, a comprehensive framework developed to aid cancer programs and practices deliver services to patients that prevent, detect, and mitigate financial hardship during cancer care.
Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV.
